Welcome to our dedicated page for Meiragtx Holdings Plc news (Ticker: MGTX), a resource for investors and traders seeking the latest updates and insights on Meiragtx Holdings Plc stock.
MeiraGTx Holdings plc (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicines company. Its news flow centers on clinical trial readouts, regulatory designations, strategic collaborations and manufacturing milestones across a broad pipeline in ophthalmology, Parkinson’s disease, radiation-induced xerostomia and other genetic medicine programs.
News updates from MeiraGTx frequently cover progress in late-stage clinical programs such as AAV-AIPL1 for Leber congenital amaurosis 4, AAV2-hAQP1 for radiation-induced xerostomia and AAV-GAD for Parkinson’s disease. The company issues releases on data presented at scientific meetings, including results from randomized, double-blind, sham-controlled studies and first-in-human trials in rare pediatric retinal dystrophies.
Investors and observers can also follow announcements about regulatory interactions, including Regenerative Medicine Advanced Therapy (RMAT) designations, orphan and Rare Pediatric Disease designations, and plans for marketing authorization applications and biologics license applications in the United States, United Kingdom and European Union. These items provide context on potential development pathways for MeiraGTx’s investigational therapies.
Another recurring theme in MeiraGTx news is strategic partnering. The company has reported a collaboration and license agreement with Eli Lilly and Company in ophthalmology, as well as a broad collaboration with Hologen AI that includes the formation of Hologen Neuro AI Ltd to advance AAV-GAD and other central nervous system programs. Updates on its relationship with Johnson & Johnson Innovative Medicine around botaretigene sparoparvovec for X-linked retinitis pigmentosa also appear in its news feed.
In addition, MeiraGTx news items highlight developments in its riboswitch gene regulation platform, promoter and capsid engineering research, and expansions of its GMP manufacturing capabilities in the United Kingdom and Ireland. Visitors to this page can review these releases to understand how MeiraGTx’s clinical, regulatory, technological and manufacturing activities evolve over time.
MeiraGTx (NASDAQ:MGTX), a clinical-stage genetic medicines company, reported significant progress across multiple programs in Q2 2025. The company achieved FDA alignment on its Phase 2 AQUAx2 study for radiation-induced xerostomia and received RMAT designation for AAV-GAD in Parkinson's disease treatment.
Key developments include plans to file for Marketing Authorization Approval with MHRA and BLA with FDA for LCA4 treatment in Q4 2025. The company's strategic collaboration with Hologen includes $200 million in cash consideration and formation of Hologen Neuro AI Ltd joint venture with up to $230 million additional funding.
Financial position shows $32.2 million in cash as of June 30, 2025, with additional receivables and expected proceeds sufficient to fund operations into 2027.
MeiraGTx (Nasdaq: MGTX) presented four posters at the ASGCT 2025 Annual Meeting showcasing their gene and cell therapy technology platforms. Key presentations included:
1. An ultra-low dose CNS gene therapy for pediatric obesity using optimized BDNF clinical construct, showing 40% weight loss in mice vs 12% with semaglutide
2. Novel CAG-based promoters that are shorter and more potent than traditional ones, with one variant (C178) showing superior performance in muscle, liver, heart, and brain while being 700 base pairs shorter
3. Research on transcription factor binding sites (TFBS) to enhance synthetic promoter activity, identifying optimal combinations for gene expression
4. Development of optimized AAV-hUPF1 gene therapy for ALS and FTD, showing improved efficacy in multiple disease models while reducing construct size by 1.5kb
MeiraGTx (NASDAQ: MGTX) announced significant developments in Q4 2024 and early 2025, highlighted by a strategic collaboration with Hologen AI including a $200 million upfront payment and formation of Hologen Neuro AI joint venture with $230 million additional committed capital.
Key achievements include: positive data from AAV-GAD Parkinson's disease clinical study showing significant UPDRS Part 3 improvements; FDA Regenerative Medicine Advanced Therapy designation for AAV2-hAQP1 xerostomia treatment; and exceptional clinical results for LCA4 gene therapy with 100% response rate in treated children.
The company ended 2024 with $103.7 million in cash and expects sufficient funding into 2027, including the Hologen collaboration proceeds. Additional potential revenue includes $285 million in milestone payments upon first commercial sales of bota-vec in US and EU.
MeiraGTx (MGTX) has announced a strategic collaboration with Hologen AI, receiving $200 million upfront and forming a joint venture called Hologen Neuro AI The venture will receive $230 million in committed capital from Hologen to fund AAV-GAD development for Parkinson's disease through commercialization.
The joint venture combines MeiraGTx's genetic medicines expertise with Hologen's AI capabilities. MeiraGTx will retain 30% ownership in the venture and lead clinical development and manufacturing. The company's AAV-GAD program is Phase 3 ready, with positive data reported in October 2024 showing an 18-point improvement in UPDRS Part 3 scores at 26 weeks.
The collaboration includes exclusive manufacturing agreements and Hologen taking a minority stake in MeiraGTx's manufacturing subsidiary. The deal is expected to close in Q2 2025, subject to regulatory approvals.
MeiraGTx announced groundbreaking results published in The Lancet for their gene therapy treatment rAAV8.hRKp.AIPL1 targeting Leber Congenital Amaurosis 4 (LCA4), a severe form of inherited blindness. The clinical study demonstrated remarkable efficacy in all 11 treated children who were legally blind at birth.
The first cohort of 4 children received unilateral treatment, showing improved visual acuity from light perception to 0.9 LogMAR. A second cohort of 7 children received bilateral treatment, with all participants showing substantial benefits. The treatment demonstrated protection against progressive retinal degeneration without serious adverse effects.
Following these exceptional results, MeiraGTx plans to submit a Marketing Authorization Application to the MHRA under exceptional circumstances, with no additional clinical data required. The company is also engaging with the FDA for expedited approval in the United States. The treatment has received orphan drug and rare pediatric disease designations from the FDA and orphan designation from the European Commission.
MeiraGTx (NASDAQ: MGTX) has received Rare Pediatric Disease Designation (RPDD) from the FDA for its AAV8-RK-RetGC program, targeting Leber congenital amaurosis due to GUCY2D mutations (LCA1). This marks the company's fourth RPDD in three months, following designations for treatments of LCA4 retinal dystrophy, Bardet-Biedl syndrome, and RDH12 associated retinal dystrophy.
The RPDD program applies to diseases affecting fewer than 200,000 U.S. patients, primarily under 18 years old. If approved, MeiraGTx may receive a Priority Review Voucher (PRV), which can be used or sold, with recent PRVs selling for between $100-158 million. The company plans to leverage its manufacturing infrastructure and Specials License to accelerate the development of these treatments for childhood blinding conditions.
MeiraGTx has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for AAV2-hAQP1, targeting Grade 2/3 radiation-induced xerostomia (RIX). This designation, granted to less than half of applicants, includes benefits of Fast Track and Breakthrough Therapy designations, enabling increased FDA interaction and potential accelerated approval.
The therapy showed promising results in the Phase 1 AQUAx clinical trial, demonstrating significant improvements in patient-reported outcomes and saliva production, with no treatment-related serious adverse events. The ongoing Phase 2 AQUAx2 study is a randomized, double-blind, placebo-controlled trial across multiple sites in the U.S., Canada, and U.K., which could potentially support a BLA filing.
MeiraGTx announced significant Q3 2024 developments, including three FDA Rare Pediatric Disease Designations for inherited retinal therapies. The company reported positive data from its AAV-GAD Parkinson's disease study, showing significant improvements in key efficacy endpoints. The MHRA agreed to review a Marketing Authorization Application for AAV-AIPL1 without further clinical studies. Financial highlights include $122.9 million in cash and equivalents, with funding projected into Q2 2026. Q3 service revenue was $10.9 million, with a net loss of $39.3 million ($0.55 per share), compared to $44.3 million ($0.74 per share) in Q3 2023.